Epidemiology of extended-spectrum β-lactamase-producing Enterobacterales in five US sites participating in the Emerging Infections Program, 2017.
Journal
Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
pubmed:
15
2
2022
medline:
22
11
2022
entrez:
14
2
2022
Statut:
ppublish
Résumé
The incidence of infections from extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E) is increasing in the United States. We describe the epidemiology of ESBL-E at 5 Emerging Infections Program (EIP) sites. During October-December 2017, we piloted active laboratory- and population-based (New York, New Mexico, Tennessee) or sentinel (Colorado, Georgia) ESBL-E surveillance. An incident case was the first isolation from normally sterile body sites or urine of We identified 884 incident cases. The estimated annual incidence in sites conducting population-based surveillance was 199.7 per 100,000 population. Overall, 800 isolates (96%) were from urine, and 790 (89%) were The burden of ESBL-E was high across surveillance sites, with nearly half of cases acquired in the community. EIP has implemented ongoing ESBL-E surveillance to inform prevention efforts, particularly in the community and to watch for the emergence of new ESBL-E strains.
Identifiants
pubmed: 35156596
pii: S0899823X21004967
doi: 10.1017/ice.2021.496
pmc: PMC9375772
mid: NIHMS1806924
doi:
Substances chimiques
beta-Lactamases
EC 3.5.2.6
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1586-1594Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Références
Antimicrob Agents Chemother. 2014;58(1):212-20
pubmed: 24145532
Lancet Infect Dis. 2019 Dec;19(12):1325-1335
pubmed: 31653524
Infect Dis Clin North Am. 2020 Dec;34(4):677-708
pubmed: 33011052
J Clin Microbiol. 2005 Aug;43(8):4178-82
pubmed: 16081970
Lancet Infect Dis. 2017 May;17(5):528-537
pubmed: 28238601
Clin Microbiol Infect. 2010 Jan;16(1):33-8
pubmed: 19681957
JAMA. 2018 Sep 11;320(10):984-994
pubmed: 30208454
Lancet Infect Dis. 2017 Jan;17(1):78-85
pubmed: 27751772
Mol Microbiol. 2006 Jun;60(5):1136-51
pubmed: 16689791
Lancet Planet Health. 2019 Aug;3(8):e357-e369
pubmed: 31439317
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Glob Antimicrob Resist. 2021 Jun;25:93-101
pubmed: 33746112
N Engl J Med. 2020 Apr 2;382(14):1309-1319
pubmed: 32242356
J Clin Microbiol. 2021 May 19;59(6):
pubmed: 33827899
Lancet Infect Dis. 2019 Apr;19(4):419-428
pubmed: 30846277
BMC Genomics. 2008 Nov 26;9:560
pubmed: 19036134
J Environ Public Health. 2019 Feb 18;2019:3862949
pubmed: 30906330
Infect Control Hosp Epidemiol. 2017 Oct;38(10):1209-1215
pubmed: 28758612
J Antimicrob Chemother. 2012 Nov;67(11):2640-4
pubmed: 22782487
JAMA. 2015 Oct 13;314(14):1479-87
pubmed: 26436831
Euro Surveill. 2019 Oct;24(41):
pubmed: 31615600
Clin Infect Dis. 2013 Mar;56(5):641-8
pubmed: 23150211
Emerg Infect Dis. 2019 Jan;25(1):
pubmed: 30561323
Front Microbiol. 2021 Apr 12;12:617349
pubmed: 33912141
J Infect Dis. 2016 Jan 1;213(1):6-13
pubmed: 26333944
Lancet Infect Dis. 2008 Mar;8(3):159-66
pubmed: 18291338
Clin Infect Dis. 2009 Jul 15;49(2):e30-2
pubmed: 19522654
J Hosp Infect. 2020 Nov;106(3):419-428
pubmed: 32918969
Infect Control Hosp Epidemiol. 2020 Mar;41(3):286-294
pubmed: 31822301
Genome Res. 2020 Jan;30(1):138-152
pubmed: 31809257
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Open Forum Infect Dis. 2019 Jan 03;6(2):ofy357
pubmed: 30775401
Emerg Infect Dis. 2015 Sep;21(9):1537-42
pubmed: 26291035
Infect Control Hosp Epidemiol. 2016 Jan;37(1):49-54
pubmed: 26458226
J Clin Microbiol. 2012 Feb;50(2):294-9
pubmed: 22162555
Antimicrob Agents Chemother. 2014;58(2):1200-2
pubmed: 24247126